Literature DB >> 1668287

Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract.

M N Aparicio-Pagés1, H W Verspaget, A S Peña, C B Lamers.   

Abstract

Natural killer (NK) cell activity and the in vitro effect of recombinant gamma interferon (r gamma-IFN) were evaluated in 12 patients with esophageal adenocarcinoma, 14 patients with gastric adenocarcinoma, 12 patients with pancreatic adenocarcinoma, and 19 healthy controls against the erythroleukemia cell line K-562. Patients with upper gastrointestinal tract carcinomas had a similar spontaneous NK cell activity as the control group. After stimulation with r gamma-IFN, however, the NK cell activity of patients with esophageal or pancreatic adenocarcinoma was significantly lower than that of patients with gastric carcinoma and that of the controls (p less than 0.05). When all patients with adenocarcinomas were classified according to the advancement of the disease, a marked impairment of NK cell activity was found in patients with advanced disease (p less than 0.01) compared to the patients with localized disease or to the controls. Although r gamma-IFN stimulated the NK cell activity of both patients and controls significantly, 62% of the patients with carcinoma and advanced disease remained below the normal spontaneous NK cell activity level even after r gamma-IFN stimulation. In conclusion, an impaired NK cell activity was found in patients with esophageal or pancreatic cancer. Patients with advanced disease were more likely to have an impaired NK cell activity than those with localized disease. The decreased NK cell activity, in particular of patients with esophageal or pancreatic carcinoma, may be related to the unfavourable prognosis of these patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1668287

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  9 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

2.  Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer.

Authors:  Xiaohui Duan; Langmei Deng; Xiong Chen; Yebin Lu; Qi Zhang; Kejing Zhang; Yongjun Hu; Jie Zeng; Weijia Sun
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

3.  Ex vivo generation of highly purified and activated natural killer cells from human peripheral blood.

Authors:  Satoru Saito; Yui Harada; Yosuke Morodomi; Mitsuho Onimaru; Kumi Yoshida; Ryoichi Kyuragi; Hisahiro Matsubara; Yoshikazu Yonemitsu
Journal:  Hum Gene Ther Methods       Date:  2013-08       Impact factor: 2.396

Review 4.  Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.

Authors:  Amedeo Amedei; Elena Niccolai; Domenico Prisco
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells.

Authors:  Jonas R M Van Audenaerde; Jorrit De Waele; Elly Marcq; Jinthe Van Loenhout; Eva Lion; Johan M J Van den Bergh; Ralf Jesenofsky; Atsushi Masamune; Geert Roeyen; Patrick Pauwels; Filip Lardon; Marc Peeters; Evelien L J Smits
Journal:  Oncotarget       Date:  2017-05-25

6.  Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs.

Authors:  Anna Karolina Kozlowska; Paytsar Topchyan; Kawaljit Kaur; Han-Ching Tseng; Antonia Teruel; Toru Hiraga; Anahid Jewett
Journal:  J Cancer       Date:  2017-02-11       Impact factor: 4.207

7.  Probiotic-Treated Super-Charged NK Cells Efficiently Clear Poorly Differentiated Pancreatic Tumors in Hu-BLT Mice.

Authors:  Kawaljit Kaur; Anna Karolina Kozlowska; Paytsar Topchyan; Meng-Wei Ko; Nick Ohanian; Jessica Chiang; Jessica Cook; Phyu Ou Maung; So-Hyun Park; Nicholas Cacalano; Changge Fang; Anahid Jewett
Journal:  Cancers (Basel)       Date:  2019-12-24       Impact factor: 6.639

8.  The antitumor activity of hPRDX5 against pancreatic cancer and the possible mechanisms.

Authors:  Lihua Cui; Yuanyuan Jin; Sen Zou; Jing Xun; Xiangyang Yu; Qi Zhang; Zhaoyong Yang
Journal:  Braz J Med Biol Res       Date:  2022-09-12       Impact factor: 2.904

Review 9.  Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes.

Authors:  Juan P Cata; Claudius Conrad; Katy Rezvani
Journal:  Scientifica (Cairo)       Date:  2015-10-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.